MolMed Presents New Data From Four Clinical Trials on NGR-hTNF at European Multidisciplinary Cancer Congress
(firmenpresse) - MILAN, ITALY -- (Marketwire) -- 09/27/11 -- MolMed S.p.A. (MILAN: MLM) presented new data from four clinical trials on its investigational anticancer drug NGR-hTNF at the European Multidisciplinary Cancer Congress, taking place in Stockholm on 23-27 September 2011. The Company reported updated interim results from a randomised Phase II trial in non-small-cell lung cancer, and follow-up data from two completed Phase II trials in recurrent ovarian cancer and relapsed small-cell lung cancer. The clinical development update also included results from a Phase I trial at high doses.
Claudio Bordignon, chairman and CEO of MolMed, comments: "The new interim randomised data in lung cancer look promising particularly in patients with the squamous cell histological subtype, a severe form of lung cancer with high need of new treatment options. As to new follow-up data from the two completed trials, the long-term clinical benefit in two poor-prognosis tumours such as relapsed ovarian and small-cell lung cancer, observed in patients presenting normal lymphocyte counts, confirms the dual mode by which NGR-hTNF exerts its effect, destroying the tumour vasculature and exploiting the effectors of the immune system. There is a growing need for tools, among which predictive biomarkers, to identify patients responding to a specific drug: for NGR-hTNF, a simple blood test such as lymphocyte counts correlates with clinical benefit. This parameter, together with others, might contribute in the future to the identification of patients more likely to get prolonged therapeutic benefit."
This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999, as subsequently amended.
About NGR-hTNF
NGR-hTNF is a vascular targeting agent with a unique mode of action. A first-in-class compound in the class of peptide/cytokine complexes, it is able to selectively target the tumour vasculature. It consists of a tumour homing peptide (NGR) that selectively binds tumour blood vessels, fused to the human cytokine TNF. NGR-hTNF is undergoing clinical development both as monotherapy and in combination therapy, in a total of seven indications. Currently ongoing randomised trials of NGR-hTNF include a Phase III trial in mesothelioma and four Phase II trials for non-small-cell lung cancer, soft tissue sarcomas, ovarian cancer and mesothelioma as first-line maintenance therapy. Other Phase II trials of NGR-hTNF include completed trials for mesothelioma, liver cancer, colorectal cancer, small-cell lung cancer and ovarian cancer. NGR-hTNF has been granted Orphan Drug designation for the treatment of mesothelioma and liver cancer in both the EU and the US.
About MolMed
MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemia; and NGR-hTNF, a novel vascular targeting agent (VTA), in Phase III in malignant pleural mesothelioma and in Phase II in six other indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares are listed on the Milan Stock Exchange, on the Standard segment (Class I) of the MTA managed by Borsa Italiana.
DISCLAIMER
This press release may contain certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.
Tax identification number 11887610159
Office of Milan Company Register number 11887610159
Share capital as of 30/05/2011: EUR 43,609,036.42 fully paid
Contacts:
MolMed S.p.A.
Holger Neecke
Director Business Development & Investor Relations
+39 02 21277.205
+39 02 21277.325 (FAX)
MolMed S.p.A.
Elena Lungagnani
Communication Manager
+39 02 21277.207
+39 02 21277.325 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.09.2011 - 05:26 Uhr
Sprache: Deutsch
News-ID 69726
Anzahl Zeichen: 0
contact information:
Town:
MILAN, ITALY
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MolMed Presents New Data From Four Clinical Trials on NGR-hTNF at European Multidisciplinary Cancer Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
MolMed S.p.A. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
